红霉素与甲氧氯普胺促进幽门后螺旋鼻肠管置入:随机非劣效性试验
该研究为前瞻性、多中心、开放标签、平行非劣效性随机对照试验,纳入中国8家三级医院ICU中计划置入鼻肠管的重症患者332例,比较红霉素与甲氧氯普胺促进螺旋鼻肠管幽门后置入的效果。主要终点为置管24小时后腹部X线确认鼻肠管到达十二指肠第一段或更远。意向性分析显示,红霉素组置管成功率为57.5%(96/167),甲氧氯普胺组为50.3%(83/165),差值7.2%(95%CI -3.5%至17.9%),未包括预设非劣效界值-10%。到达十二指肠第二段及更远、第三段及更远、第四段及更远以及近端空肠的置管成功率及任何不良事件发生率两组间均无显著差异。结论认为红霉素在促进重症患者螺旋鼻肠管幽门后置入方面不劣于甲氧氯普胺。
要点
- 在ICU计划置入螺旋鼻肠管的重症患者中,红霉素组幽门后置管成功率为57.5%(96/167),甲氧氯普胺组为50.3%(83/165),差值7.2%(95%CI -3.5%至17.9%),未包括预设非劣效界值-10%。
- 红霉素与甲氧氯普胺在到达十二指肠第二段及更远、第三段及更远、第四段及更远以及近端空肠的置管成功率上均无显著差异。
- 两组任何不良事件发生率无显著差异。
- 该研究为前瞻性、多中心、开放标签、平行非劣效性随机对照试验,纳入中国8家三级医院ICU的332例患者。
适用人群与场景
- 中国8家三级医院ICU收治的重症患者,计划置入鼻肠喂养管者。
- 共筛查5688例ICU患者,其中355例计划置入鼻肠管,332例随机分组。
研究设计与关键结果
- 研究类型:前瞻性、多中心、开放标签、平行非劣效性随机对照试验,纳入中国8家三级医院ICU的332例重症患者。
- 干预与对照:红霉素组167例 vs 甲氧氯普胺组165例。
- 主要终点:置管24小时后腹部X线确认螺旋鼻肠管到达十二指肠第一段或更远的幽门后置管成功率,红霉素组57.5%(96/167) vs 甲氧氯普胺组50.3%(83/165),差值7.2%(95%CI -3.5%至17.9%),未包括预设非劣效界值-10%。
- 关键次要终点:到达十二指肠第二段及更远、第三段及更远、第四段及更远以及近端空肠的置管成功率两组间均无显著差异。
- 不良事件:任何不良事件发生率两组间无显著差异。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、开放标签、平行非劣效性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU计划置入螺旋鼻肠管的重症患者中,红霉素促进幽门后置管的不劣于甲氧氯普胺,作者结论认为红霉素非劣于甲氧氯普胺。
- 两组到达十二指肠第二段及更远、第三段及更远、第四段及更远以及近端空肠的置管成功率无显著差异,任何不良事件发生率无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To determine whether erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of self-propelled spiral nasoenteric tubes (NETs) in critically ill patients.
METHODS: A prospective, multicenter, open-label, parallel, and non-inferiority randomized controlled trial was conducted comparing erythromycin with metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients admitted to intensive care units (ICUs) of eight tertiary hospitals in China. The primary outcome was procedure success defined as post-pyloric placement (spiral NETs reached the first portion of the duodenum or beyond confirmed by abdominal radiography 24 h after tube insertion).
RESULTS: A total of 5688 patients were admitted to the ICUs. Of these, in 355 patients there was a plan to insert a nasoenteric feeding tube, of whom 332 were randomized, with 167 patients assigned to the erythromycin group and 165 patients assigned to the metoclopramide group. The success rate of post-pyloric placement was 57.5% (96/167) in the erythromycin group, as compared with 50.3% (83/165) in the metoclopramide group (a difference of 7.2%, 95% CI - 3.5% to 17.9%), in the intention-to-treat analysis, not including the prespecified margin of - 10% for non-inferiority. The success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond), and proximal jejunum placement and the incidence of any adverse events were not significantly different between the groups.
CONCLUSIONS: Erythromycin is non-inferior to metoclopramide in facilitating post-pyloric placement of spiral NETs in critically ill patients. The success rates of post-D1, post-D2, post-D3, and proximal jejunum placement were not significantly different.
参考来源
- Hu B, Ouyang X, Lei L, et al. Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial. Intensive Care Med. 2018. PMID: 30465070. doi:10.1007/s00134-018-5466-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。